(Sharecast News) - Drugmaker Astrazeneca said the US Food and Drug Administration had pushed back its decision on camizestrant after requesting additional data for the drug's new application.
Astrazeneca had been seeking approval for camizestrant to be used alongside a CDK4/6 inhibitor as a first‑line treatment for patients with HR‑positive, HER2‑negative...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE